Psychotropic medication – endocrine consequences

Authors: Georgiana Taujan, Diana Paun, Mihaela Nistor, Alina Dumitru, Adina Dragomir, Ruxandra Hristea, Constantin Dumitrache
Gonadal and Adrenal Pathology Department, National Institute of Endocrinology C. I. Parhon, Bucharest, Romania

Introduction
Given the increasing incidence in psychiatric pathology, adverse reactions of psychotropic medications, especially the metabolic and endocrine side effects, are encountered more frequently in clinical practice.

We present the cases of two patients with psychiatric pathology, in whom the specific treatment was accompanied by significant endocrine adverse reactions, making the tumor differential diagnosis very difficult.

Case 1
61 years old female presented to our clinic in 02.2015 for severe virilizing syndrome.

Patient’s medical history
- reached menopause at 52 years old
- schizophrenia from the age 27 years, now treated with aripiprazole, valproate and dexamethasone
- hypertension from age 54, treated with β-blockers, ACE inhibitors and calcium blockers

Clinical examination
- was within normal limits.
- Endocrinological examination revealed severe hirsutism installed progressively in recent years (apparently after initiation of valproate therapy) with androgenic alopecia

Paraclinical investigations:
- Hematological and biochemical test with normal values
- Hormonal tests
  - Normal TSH, free T4
  - Very high basal serum testosterone (9.2 ng/ml, VNL:0.1 - 0.75 ng/ml), with no response following 1mg dexamethasone suppression test

- Normal SHBG and DHEA-S
- LH, FSH, estradiol with inadequate values for menopause (suggestive for androgen hypersecretion in a woman at menapausal age)

- Serum cortisol with normal response in 1mg dexamethasone suppression test

- Normal plasma mannosephosphatemine, normocytopenia, andalsteron and HCG

Abdominal and pelvic CT scan with contrast: ovoid, homogenous, well-defined mass in left adrenal gland, of 243.221cm, with 22UH-33UH spontaneous density and 30UH-37UH after contrast administration; two homogenous u terine masses of 2.9/2.4/2.8cm and 2.6/1.3/1.5cm; without ovarian tumors.

Transvaginal ultrasound:
- two uterine fibroids measuring 33/29mm, respectively 25/20mm; echogenic endometrium of 6mm thickness; small ovaries, both with a cystic aspect of 15/12mm, respective 10/5mm.

Diagnoses:
- Ovarian hyperthecosis secondary to valproate treatment with severe virilizing syndrome
- Uterine fibroids
- Arterial hyperthecosis stage II H7C7
- Schizophrenia

Differential diagnosis:
- Androgen secreting tumor vs. pharmacological hyperandrogenism
- Adrenal androgen secreting tumor vs. ovarian androgen secreting tumor
- Essential hypertension vs. secondary hypertension
- Menopause vs. secondary amenorrhea

We considered the patient having valproate induced hyperandrogenism due to ovarian hyperthecosis because:

- Very high testosterone levels with low-normal value of DHEA-S
- Lack of response of serum testosterone in the same test
- Normal response of serum cortisol in 1mg DEX overnight test
- CT characteristics of the adrenal mass and lack of ovarian tumors
- Slow progressive evolution of the virilizing syndrome in the past 8 years, after initiation of valproate treatment.

We referred the patient to gynecologist for bilateral oophorectomy. The histopathological examination confirmed the diagnosis. The patient will be re-evaluated for the adrenal mass 6 months after the first CT scan.

Discussion: Although valproate therapy is frequently associated with ovarian polycystic syndrome in young women, in our case, the therapy was associated with ovarian hyperthecosis with severe virilizing syndrome in a postmenopausal woman which is a rare but important cause of serum testosterone levels in the neoplastic region.

References:
2. Daria La Torre, Alberto Falorni. Pharmacological causes of hyperprolactinemia. Therapeutics and Medical Risk Management 2007;3 (5) 929-951

Case 2
24 years old female patient, presented in our clinic in 02.2015 for amenorrhea-galactorrhea syndrome

Patient’s medical history:
- recently diagnosed with depressive disorder, for which valproate and escitalopram treatment was started 5 months prior presentation.
- Patient denies using any other drugs (including oral contraceptives) or taking dietary supplements in the last 2 years.
- Clinical examination was within normal limits.
- Endocrinological examination revealed amenorrhea with bilateral galactorrhea, without headache or visual field disturbances, with no hirsutism or pathological stria.

Paraclinical investigations:
- Hematological and biochemical test with normal values (excluding hepatic or renal diseases)
- Negative pregnancy test
- Hormonal tests
  - very high serum prolactin (224 ng/ml, NV: 3-27 ng/ml)
  - low-normal FSH and LH, with low serum estradiol
  - normal serum testosterone, SHBG, DHEA-S
  - normal TSH, free T4

<table>
<thead>
<tr>
<th>Text</th>
<th>Result</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSH</td>
<td>4.19</td>
<td>2.85-7.25 IU/l</td>
</tr>
<tr>
<td>LH</td>
<td>14.5</td>
<td>0.4-1.0 IU/l</td>
</tr>
<tr>
<td>Testosterone</td>
<td>0.65</td>
<td>0.05-0.15 nmol/l</td>
</tr>
</tbody>
</table>

Pituitary CT scan revealed a normal sized pituitary gland with left sided small hypopussenting nodule, with low enhancement after the contrast administration, measuring 0.40x0.4cm, with no displacement of the pituitary stalk.

Diagnoses:
- Pharmacological hyperprolactinemia
- Pituitary microadenoma
- Depressive disorder treated with valproate and SSRI

Differential diagnostics:
- Tumoral vs pharmacological hyperprolactinemia
- Secondary amenorrhea vs premature ovarian failure

We referred the patient to the psychiatrist for evaluation of the depressive disorder treatment. Soon after excluding escitalopram, the patient reported remission of the galactorrhea and resuming rhythmic menstrual cycles.

This patient will also be re-evaluated 6 months after the first pituitary CT scan, in order to determine the evolution of the pituitary incidentia.

Discussions: SSRI are considered the most common cause of pharmacological hyperprolactinemia; most frequently reported are sertraline, fluoxetine and paroxetine. Escitalopram is one of the most popular new generation SSRI and is indicated as first-line in the treatment of depression. Escitalopram-associated hyperprolactinemia is considered a rare adverse reaction, with only a few reports in the literature.

Conclusion
In both cases, CT scans revealed incidentalomas (adrenal, respective pituitary) rising important issues regarding differential diagnostics.
Although endocrine side effects of psychotropic therapy are not life threatening and are less frequent than neurological side effects, such as sedation, extrapyramidal syndrome and cholinergic disorders, recognizing and correcting them (by changing the therapeutic agent) is the key to a successful therapy and ensures patient compliance.